Te Ahumairangi Investment Management Ltd Has $8.18 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Te Ahumairangi Investment Management Ltd lifted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 50,765 shares of the company's stock after acquiring an additional 4,640 shares during the period. Johnson & Johnson accounts for 1.5% of Te Ahumairangi Investment Management Ltd's portfolio, making the stock its 18th biggest holding. Te Ahumairangi Investment Management Ltd's holdings in Johnson & Johnson were worth $8,180,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. AlphaMark Advisors LLC lifted its stake in shares of Johnson & Johnson by 5.3% in the 2nd quarter. AlphaMark Advisors LLC now owns 1,517 shares of the company's stock worth $222,000 after acquiring an additional 76 shares during the period. Corundum Group Inc. increased its position in shares of Johnson & Johnson by 28.9% during the 2nd quarter. Corundum Group Inc. now owns 11,067 shares of the company's stock valued at $1,618,000 after purchasing an additional 2,478 shares during the period. Red Door Wealth Management LLC raised its stake in shares of Johnson & Johnson by 4.5% in the 2nd quarter. Red Door Wealth Management LLC now owns 49,458 shares of the company's stock worth $7,229,000 after buying an additional 2,136 shares in the last quarter. Blackston Financial Advisory Group LLC lifted its holdings in shares of Johnson & Johnson by 201.9% in the second quarter. Blackston Financial Advisory Group LLC now owns 4,275 shares of the company's stock valued at $625,000 after buying an additional 2,859 shares during the period. Finally, Welch Group LLC boosted its stake in Johnson & Johnson by 3.2% during the second quarter. Welch Group LLC now owns 337,096 shares of the company's stock valued at $49,270,000 after buying an additional 10,331 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have weighed in on JNJ. Royal Bank of Canada upped their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an "outperform" rating in a report on Wednesday, October 16th. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Wells Fargo & Company raised their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 16th. Guggenheim boosted their target price on Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 6th. Finally, StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, September 14th. Seven analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $174.73.

Johnson & Johnson Stock Down 0.3 %

Shares of NYSE JNJ traded down $0.40 during trading hours on Thursday, hitting $146.24. The stock had a trading volume of 6,126,822 shares, compared to its average volume of 7,118,491. The company has a market capitalization of $352.09 billion, a P/E ratio of 21.28, a P/E/G ratio of 2.66 and a beta of 0.51. The firm's 50-day moving average price is $157.29 and its two-hundred day moving average price is $156.35. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson's quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.66 EPS. Analysts anticipate that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th were issued a dividend of $1.24 per share. The ex-dividend date was Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.39%. Johnson & Johnson's dividend payout ratio (DPR) is presently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.